Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.

× No keyword cloud information.

12 in total

1. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.

Authors: M Dowsett; D C Cunningham; R C Stein; S Evans; L Dehennin; A Hedley; R C Coombes
Journal: Cancer Res Date: 1989-03-01 Impact factor: 12.701

2. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.

Authors: D J Perrault; D M Logan; D J Stewart; V H Bramwell; A H Paterson; E A Eisenhauer
Journal: Invest New Drugs Date: 1988-09 Impact factor: 3.850

3. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).

Authors: J M Kuhn; T Billebaud; H Navratil; A Moulonguet; J Fiet; P Grise; J F Louis; P Costa; J M Husson; R Dahan
Journal: N Engl J Med Date: 1989-08-17 Impact factor: 91.245

4. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

Authors: M Dowsett; P E Goss; T J Powles; G Hutchinson; A M Brodie; S L Jeffcoate; R C Coombes
Journal: Cancer Res Date: 1987-04-01 Impact factor: 12.701

5. Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity.

Authors: W R Miller; J Telford; J M Dixon; R A Hawkins
Journal: Eur J Cancer Clin Oncol Date: 1985-04

6. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer.

Authors: A Manni; B M Arafah; O H Pearson
Journal: Cancer Date: 1981-12-01 Impact factor: 6.860

7. Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: a multivariate analysis approach.

Authors: M M Brentani; E L Franco; C T Oshima; M M Pacheco
Journal: Int J Cancer Date: 1986-11-15 Impact factor: 7.396

8. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.

Authors: A Howell; J Mackintosh; M Jones; J Redford; J Wagstaff; R A Sellwood
Journal: Eur J Cancer Clin Oncol Date: 1988-10

9. Androgen receptors in breast cancer.

Authors: R M Bryan; R J Mercer; R C Bennett; G C Rennie; T H Lie; F J Morgan
Journal: Cancer Date: 1984-12-01 Impact factor: 6.860

10. Oestrogen-related changes in sex hormone binding globulin levels during normal and gonadotrophin-stimulated menstrual cycles.

Authors: M Dowsett; S L Attree; S S Virdee; S L Jeffcoate
Journal: Clin Endocrinol (Oxf) Date: 1985-09 Impact factor: 3.478

4 in total

Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.